Advertisement
Canada markets close in 5 hours 2 minutes
  • S&P/TSX

    22,010.44
    +138.48 (+0.63%)
     
  • S&P 500

    5,068.20
    +57.60 (+1.15%)
     
  • DOW

    38,507.63
    +267.65 (+0.70%)
     
  • CAD/USD

    0.7317
    +0.0016 (+0.22%)
     
  • CRUDE OIL

    82.24
    +0.34 (+0.42%)
     
  • Bitcoin CAD

    91,502.22
    +886.87 (+0.98%)
     
  • CMC Crypto 200

    1,439.01
    +24.25 (+1.71%)
     
  • GOLD FUTURES

    2,329.50
    -16.90 (-0.72%)
     
  • RUSSELL 2000

    2,002.34
    +34.86 (+1.77%)
     
  • 10-Yr Bond

    4.5880
    -0.0350 (-0.76%)
     
  • NASDAQ

    15,683.19
    +231.89 (+1.50%)
     
  • VOLATILITY

    16.28
    -0.66 (-3.90%)
     
  • FTSE

    8,037.30
    +13.43 (+0.17%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6835
    -0.0015 (-0.22%)
     

ZY ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2021 in the Class Action Filed on Behalf of Zymergen Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - September 17, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Zymergen Inc. (NASDAQ: ZY) alleging that the Company violated federal securities laws.

This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.
Lead Plaintiff Deadline: October 4, 2021
No obligation or cost to you.

Learn more about your recoverable losses in ZY:
https://www.kleinstocklaw.com/pslra-1/zymergen-inc-loss-submission-form?id=19684&from=5

Zymergen Inc. NEWS - ZY NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Zymergen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

ADVERTISEMENT

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Zymergen you have until October 4, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Zymergen securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the ZY lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96942